By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence The U.S. Department of Health and Human Services Secretary issued a notice declaring the enterovirus D68 (EV-D68) poses a “significant potential for a public health emergency that has a significant...

By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Oncotype DX assay (Genomic Health; Redwood City, Calif.), to assess a patient's risk of recurrence, was adopted quickly in clinical practice after Medicare's positive coverage decision,...

By Ron Shinkman, Editor, Laboratory Industry Report A new clinical study conducted in conjunction with the Texas-based Castle Biosciences, Inc. suggests that its molecular assay for melanoma patients can assist in determining whether their particular cancer will...

By Christopher P. Young, Editor, G2 Compliance Advisor The Medicare physician fee schedule (MPFS) will be adjusted to reflect a 21.2 percent negative update effective April 1 unless Congress acts to override or delay the cut as has been the case in previous years....

By Stephanie Murg, Managing Director, G2 Intelligence No discussion of next-generation sequencing (NGS) is complete without a reference to the swiftly plummeting cost of the technology, and yet little effort has made to put a dollar figure on the value of this type...